- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Adjuvant Pembrolizumab Significantly Improves DFS in Renal Cell Carcinoma
June 3rd 2021, 9:00pm
Pembrolizumab was associated with a 32% reduction in the risk of disease recurrence or death compared with placebo as an adjuvant treatment for patients with clear cell renal cell carcinoma.
Olaparib Provides Meaningful Benefit 1 Year After Standard of Care Therapies in BRCA1/2+, High-Risk, Early HER2- Breast Cancer
June 3rd 2021, 9:00pm
Olaparib demonstrated clinically meaningful benefit 1 year after standard of care therapies, such as surgery, chemotherapy, hormone therapy, or radiation therapy, in patients with BRCA1/2-mutant, early HER2-negative breast cancer who are at a high risk for recurrence.
Adjuvant Chemotherapy Fails to Improve PFS and OS in Locally Advanced Cervical Cancer
June 3rd 2021, 9:00pm
The administration of adjuvant carboplatin and paclitaxel following standard cisplatin-based chemoradiation failed to demonstrate an improvement in progression-free survival or overall survival in women with locally advanced cervical cancer, according to findings from the phase 3 OUTBACK trial.
Frontline Toripalimab Plus Gemcitabine/Cisplatin Significantly Improves PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma
June 3rd 2021, 9:00pm
The addition of the immunotherapy agent toripalimab to gemcitabine plus cisplatin demonstrated superior progression-free survival compared with chemotherapy alone in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma, according to data from the phase 3 JUPITER-02 trial.
Cancer Experts Preview Pivotal Trials at ASCO 2021
May 28th 2021, 7:00pm
Experts in breast cancer, gynecologic malignancies, lung cancer, multiple myeloma, gastrointestinal cancers, and genitourinary cancers shared their perspectives on the biggest abstracts being presented at the 2021 ASCO Annual Meeting.
States With Lower Medicaid Eligibility Limits May Have Worse Survival Rates Among Patients with Cancer
May 19th 2021, 9:01pm
Patients with cancer who live in states with lower Medicaid income eligibility limits had worse long-term survival outcomes compared with those with higher eligibility limits.
Relatlimab Plus Nivolumab More Than Doubles PFS in Frontline Advanced Melanoma
May 19th 2021, 9:00pm
The addition of relatlimab to nivolumab more than doubled the median progression-free survival compared with nivolumab alone in patients with previously untreated, unresectable or metastatic melanoma.
Adjuvant Atezolizumab Significantly Improves DFS in Early-Stage NSCLC
May 19th 2021, 9:00pm
Adjuvant treatment with atezolizumab led to a significant improvement in disease-free survival vs best supportive care in patients with stage II to IIIA non–small cell lung cancer, particularly those with PD-L1–positive tumors, according to findings from the phase 3 IMpower010 trial.
Increased PSA Screening Reduces Prostate Cancer–Specific Mortality in Younger African Americans
May 19th 2021, 9:00pm
An increase in the frequency of prostate-specific antigen (PSA) screening was associated with a nearly 25% reduction in prostate cancer–specific mortality in younger African Americans, according to data from a study presented in a presscast held ahead of the 2021 ASCO Annual Meeting.
Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung Cancer
May 18th 2021, 10:43pm
Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.
Dr. Doroshow on the Importance of Modernizing Clinical Trials After COVID-19
May 18th 2021, 9:24pm
James H. Doroshow, MD, discusses the importance of modernizing clinical trials in the post–COVID-19 era.
Modernized Clinical Trials Include Diverse Representation, Decentralization, and Real-World Data in Post–COVID-19 Era
May 18th 2021, 6:20pm
Silver linings of the COVID-19 pandemic have opened the door for new opportunities for decentralized clinical trials and real-world data in a post–COVID-19 world.
TIL-Based Therapies Possess Potential for Cure in Metastatic Melanoma, But Questions Remain
May 18th 2021, 2:00pm
Tumor-infiltrating lymphocytes, a neoantigen-targeting therapy, has been shown to be a potentially curative treatment for patients with metastatic melanoma, and has led to clinical responses in this population even after failure with checkpoint inhibitors
Dr. Marron on the Population Included in a Phase 1 Study of PGV-001 Neoantigen Cancer Vaccine
May 13th 2021, 9:03pm
Thomas Urban Marron, MD, PhD, describes the patient population included in a phase 1 study examining the use of PGV-001, a neoantigen cancer vaccine, across different malignancies.
Dr. Matasar on the Rationale for Combining Copanlisib and Rituximab in Indolent NHL
May 13th 2021, 8:47pm
Matthew J. Matasar, MD, Memorial Sloan Kettering Cancer Center Bergen, discusses the rationale for combining copanlisib and rituximab in patients with indolent non-Hodgkin lymphoma.
Dr. Le on Next Steps With Poziotinib in EGFR+ or HER2+ Exon 20 NSCLC
May 12th 2021, 5:21pm
Xiuning Le, MD, PhD, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR-positive or HER2-positive exon 20–mutant non–small cell lung cancer.
Dr. Hassan on the Mechanism of Action of Talazoparib in TNBC
May 12th 2021, 5:11pm
Saima Hassan, MD, PhD, FRCSC, discusses the mechanism of action of talazoparib in triple-negative breast cancer.
High-Grade ILD Prevention With Trastuzumab Deruxtecan Includes Early Detection, Optimal Management in HER2+ Metastatic Breast Cancer
May 8th 2021, 8:01pm
Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.
Datopotamab Deruxtecan Shows Encouraging Preliminary Safety, Efficacy in TNBC
May 8th 2021, 3:54pm
The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.
Retesting for HER2 Upon Breast Cancer Relapse May Provide New Therapeutic Opportunities
May 8th 2021, 10:45am
Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.